ReviewPflugers Archiv : European journal of physiology2015
Current understanding of sarcopenia: possible candidates modulating muscle mass.
Review in Pflugers Archiv : European journal of physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.
- The effectiveness of protein supplementation combined with resistance exercise programs among community-dwelling older adults with sarcopenia: a systematic review and meta-analysis.Epidemiology and health · 2024Pooled it
- Human skeletal muscle macrophages increase following cycle training and are associated with adaptations that may facilitate growth.Scientific reports · 2019Trial
- Identifying regulatory muscle processes in infantile and adult Pompe patients using a multi-omic and morphological approach.Brain pathology (Zurich, Switzerland) · 2026Article
- A Liposomal Strategy for Dual-Action Therapy in Sarcopenia: Co-Delivery of Caffeine and HAMA.International journal of molecular sciences · 2025Article
- Plasma Extracellular Vesicles Biomarkers Linked to Lower Muscle Mass, Function and Physical Performance in Sarcopenia.Journal of cachexia, sarcopenia and muscle · 2025Article
- Longitudinal changes of body composition during a 3-year follow-up in Taiwan adults with type 2 diabetes.BMJ nutrition, prevention & health · 2025Article
- Therapeutic strategies to modulate gut microbial health: Approaches for sarcopenia management.Histology and histopathology · 2024Review
- Acute Sarcopenia: Mechanisms and Management.Nutrients · 2024Review
- Age-related differences in the loss and recovery of serial sarcomere number following disuse atrophy in rats.Skeletal muscle · 2024Article
- Association of dietary patterns with sarcopenia in adults aged 50 years and older.European journal of nutrition · 2024Article
- Exploring the metabolomics profile of frailty- a systematic review.Journal of diabetes and metabolic disorders · 2024Review
- Understanding the Consequences of Fatty Bone and Fatty Muscle: How the Osteosarcopenic Adiposity Phenotype Uncovers the Deterioration of Body Composition.Metabolites · 2023Review
- Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?Internal and emergency medicine · 2023Review
- Long-term clinical outcomes in critically ill patients with sepsis and pre-existing low muscle mass: a retrospective cohort study.BMC anesthesiology · 2023Article
- Ursodeoxycholic acid induces sarcopenia associated with decreased protein synthesis and autophagic flux.Biological research · 2023Article
- Skeletal muscle aging and sarcopenia: Perspectives from mechanical studies of single permeabilized muscle fibers.Journal of biomechanics · 2023Review
- Muscle-Brain crosstalk in cognitive impairment.Frontiers in aging neuroscience · 2023Review
- Grape Polyphenols in the Treatment of Human Skeletal Muscle Damage Due to Inflammation and Oxidative Stress during Obesity and Aging: Early Outcomes and Promises.Molecules (Basel, Switzerland) · 2022Review
- Sarcopenia in Inflammatory Bowel Diseases: Reviewing Past Work to Pave the Path for the Future.Current treatment options in gastroenterology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The world's elderly population is expanding rapidly, and we are now faced with the significant challenge of maintaining or improving physical activity, independence, and quality of life in the elderly. Sarcopenia, the age-related loss of skeletal muscle mass, is characterized by a deterioration of muscle quantity and quality leading to a gradual slowing of movement, a decline in strength and power, increased risk of fall-related injury, and often, frailty. Since sarcopenia is largely attributed to various molecular mediators affecting fiber size, mitochondrial homeostasis, and apoptosis, the mechanisms responsible for these deleterious changes present numerous therapeutic targets for drug discovery. Muscle loss has been linked with several proteolytic systems, including the ubuiquitin-proteasome, lysosome-autophagy, and tumor necrosis factor (TNF)-α/nuclear factor-kappaB (NF-κB) systems. Although many factors are considered to regulate age-dependent muscle loss, this gentle atrophy is not affected by factors known to enhance rapid atrophy (denervation, hindlimb suspension, etc.). In addition, defects in Akt-mammalian target of rapamycin (mTOR) and serum response factor (SRF)-dependent signaling have been found in sarcopenic muscle. Intriguingly, more recent studies indicated an apparent functional defect in autophagy- and myostatin-dependent signaling in sarcopenic muscle. In this review, we summarize the current understanding of the adaptation of many regulators in sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.